latest news releases from the newsroom
Skandia's Market Position in Sweden
STOCKHOLM, Sweden, May 12, 2005 (PRIMEZONE) -- On 20 May the Swedish Insurance Federation will publish the industry's quarterly statistics for the first quarter of 2005. These statistics also include information about Skandia's sales development. Consequently, Skandia is today releasing sales information for the first quarter of 2005. Skandia's sales in the Swedish market were stable during the first quarter. The fee reduction for unit linked assurance that was carried out in November has not had any effect on new sales during the first quarter mainly since new sales were weaker during the first two months. However, March and April shows a positive trend within unit linked assurance.
Galapagos NV & ASINEX Ltd. Initiate Drug Discovery Collaboration in Bone and Joint Diseases
MECHELEN, Belgium and MOSCOW, May 12, 2005 (PRIMEZONE) -- Galapagos NV, a genomics-based drug discovery company and ASINEX Ltd, a worldwide leader in lead generation and optimization announce that they have initiated an integrated drug discovery collaboration in bone and joint diseases. The collaboration will result in a set of optimized leads for Galapagos' validated bone and joint disease drug targets. Financial details have not been disclosed.In the first phase of the collaboration, Galapagos' biologists will work closely with ASINEX's medicinal chemists, using ASINEX's computational chemistry expertise and proprietary chemical compound libraries to generate new leads for Galapagos' proprietary targets. The second phase will consist of the design and optimization of the lead structures. ASINEX's aim is to provide Galapagos with a patentable candidate drug series.